Syneos Health Inc - Ordinary Shares - Class A

NASDAQ:SYNH   3:59:53 PM EDT
94.45
-1.86 (-1.93%)
Products, Other Pre-Announcement

Virpax® Pharmaceuticals Receives FDA Response And Guidance On Mms019

Published: 08/17/2021 13:23 GMT
Syneos Health Inc - Ordinary Shares - Class A (SYNH) - Virpax® Pharmaceuticals Receives FDA Response and Guidance on Mms019.
Virpax Pharmaceuticals Inc - Co to Pursue Prophylactic Treatment Against Sars and Influenza for Daily Use As an Otc Product.
Virpax Pharmaceuticals Inc - Received Written Pre-investigational New Drug Response From U.S. FDA for Mms019.
Virpax Pharmaceuticals Inc - FDA Has Indicated That Co May Pursue an NDA Drug Approval With Office of Non-prescription Drugs.
Virpax - Results of Pre-ind Response Support Further Research on Mms019 As an Intranasal Protective That May Limit Transmission of Viruses to Others.
Virpax Pharmaceuticals Inc - Engaged Syneos Health to Assist With Optimal Clinical Trial Design for Mms019 Based on an Efficient Timeline.
Virpax Pharmaceuticals Inc - Expects to Move Forward and Pursue a NDA for Mms019 As a Once Daily Intranasal Treatment.